Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

Patients' expression of CEACAM5 might hold the key to activity after all.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.